<div><div></div><div><span><p><span>Roivant Sciences Ltd. reported fiscal 2026 results in its 10-K, with revenue falling to $8.26M and a net loss widening to ($299.77M), or diluted EPS of ($0.54), driven by lower license income following divestitures and higher R&amp;D investment.</span></p><p><strong><span>Financial Highlights</span></strong></p><div><table><tbody><tr><td><span>Metric</span></td><td><span>Current year</span></td><td><span>Prior year</span></td><td><span>YoY change</span></td></tr><tr><td><span>Revenue¹</span></td><td><span>$8.26M</span></td><td><span>$29.05M</span></td><td><span>(71.6%)</span></td></tr><tr><td><span>Net income²</span></td><td><span>($299.77M)</span></td><td><span>($171.98M)</span></td><td><span>(74.3%)</span></td></tr><tr><td><span>Diluted EPS³</span></td><td><span>($0.54)</span></td><td><span>($0.24)</span></td><td><span>(125%)</span></td></tr></tbody></table></div><p><em><span>¹ Reported as “Revenue”. ² Reported as “Net (loss) income attributable to Roivant Sciences Ltd.”. ³ Reported as “income per common share, diluted”.</span></em></p><p><strong><span>Business Highlights</span></strong></p><ul><li><span>Revenue and operations mix shifted after the sale of Genevant-related license streams and completed divestitures of Telavant and Dermavant, driving the revenue decline to $8.3M in 2026.</span></li><li><span>R&amp;D spending increased to support late‑stage programs including brepocitinib, IMVT‑1402 and mosliciguat; total R&amp;D rose to $681.8M for the year.</span></li><li><span>Company recognized a $770.2M litigation settlement gain and reported progress on pivotal trials and regulatory milestones that support near‑term funding stability.</span></li><li><span>Strategic divestitures monetized noncore assets and refocused capital and resources toward core &#34;Vants&#34; and clinical priorities.</span></li></ul><p><span>Original SEC Filing: </span>Roivant Sciences Ltd. [ ROIV ] - 10-K - May. 20, 2026</p><section><b><span class="heading-JaE7wgR2">Disclaimer</span></b><div><span>This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.</span></div></section></span></div></div>

ROIV

LABU

<p>Roivant Sciences Ltd. reported FY 2026 results with revenue of $8.26M, a 71.6% decline from $29.05M, and a net loss of $299.77M, widening from $171.98M. Diluted EPS fell to ($0.54). The revenue drop was attributed to lower license income and increased R&D spending, which rose to $681.8M. The company recognized a $770.2M litigation settlement gain and focused on core clinical priorities following strategic divestitures.</p>

TradingView

Roivant Sciences

Direxion S&P Biotech Bull 3X

Invesco Biotechnology & Genome ETF

Health Care Select Sector SPDR

Ark Genomic Revolution ETF

VG Health

Proshares Ultra Nasdaq Biotech

iShares Global Healthcare

ALPS Medical Breakthrough

First Trust NYSE Arca Biotech Index Fd

iShares US Pharma

iShares Biotechnology ETF

VanEck Biotech ETF

SPDR S&P Biotech

Roivant Sciences Ltd. FY 2026: Revenue $8.26M, EPS ($0.54) — 10-K Summary